You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-Cell

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • +5 more
  • (no location specified)
Aug 4, 2023

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Relapsed/Refractory B-Cell Lymphoma
  • (no location specified)
Jul 10, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • infusion of JY231 injection
  • Guangzhou, Guangdong, China
    Guangdong Second Provincial General Hospital
Sep 17, 2023

DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Loncastuximab Tesirine
  • (no location specified)
Dec 13, 2022

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • Milan, Italy
      Ospedale San Raffaele
    Aug 29, 2023

    Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • +5 more
    • La Jolla, California
    • +7 more
    Aug 25, 2023

    Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • (no location specified)
    Mar 9, 2023

    Non-hodgkin Lymphoma Trial (HY004)

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • HY004
    • (no location specified)
    Aug 21, 2023

    Relmacabtagene Autoleucel in Patients With LBCL

    Recruiting
    • Large B-cell Lymphoma
    • Relmacabtagene Autoleucel
    • Shanghai, Shanghai, China
      Ruijin Hospital Affiliated to Shanghai Jiao Tong University Scho
    Nov 15, 2023

    Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Relmacabtagene Autoleucel Injection
    • (no location specified)
    Apr 13, 2023

    B-cell Lymphoma Trial in Stockholm, Uppsala (CAR20(NAP)-T, Cyclophosphamide, Fludarabine)

    Not yet recruiting
    • B-cell Lymphoma
    • CAR20(NAP)-T
    • +2 more
    • Stockholm, Sweden
    • +1 more
    Aug 15, 2023

    Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

    Not yet recruiting
    • Relapsed/Refractory Large B-cell Lymphoma
    • (no location specified)
    Oct 6, 2023

    Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

    Completed
    • Diffuse Large B-cell Lymphoma
      • East Hanover, New Jersey
        Novartis
      Jun 16, 2023

      Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

      Not yet recruiting
      • Cancer
      • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
      • Fludarabine (30 mg/m^2)
      • +2 more
      • (no location specified)
      Jul 25, 2023

      Hematopoietic Stem Cell Transplantation, Hematologic Malignancy Trial (CliniMACS®)

      Not yet recruiting
      • Hematopoietic Stem Cell Transplantation
      • Hematologic Malignancy
      • CliniMACS®
      • (no location specified)
      Oct 17, 2023

      Frontline of ASCT in High-risk DLBCL

      Recruiting
      • Diffuse Large B Cell Lymphoma
        • Beijing, Beijing, China
          Peking University People's Hospital
        Apr 26, 2023

        Cardiovascular Events Among Adults Relapsed or Refractory

        Recruiting
        • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
        • +9 more
        • Electronic Health Record Review
        • Houston, Texas
          M D Anderson Cancer Center
        Dec 5, 2022

        B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)

        Recruiting
        • B Cell Lymphoma
        • +5 more
        • Saint Louis, Missouri
          Washington University School of Medicine
        Jan 3, 2023

        Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

        Available
        • Large B-cell Lymphoma
        • +4 more
        • Epcoritamab
        • (no location specified)
        Feb 16, 2023

        Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)

        Not yet recruiting
        • Lymphoma, Non-Hodgkin
        • +4 more
        • Birmingham, United Kingdom
        • +5 more
        Sep 18, 2023

        Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

        Recruiting
        • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
        • dualCAR-NK19/70 cell
        • Shanghai, Shanghai, China
          Shanghai Tongji Hospital, Tongji University School of Medicine
        Apr 24, 2023

        Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

        Not yet recruiting
        • Chronic Lymphocytic Leukemia
        • +2 more
        • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
        • +2 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Apr 10, 2023